Abstract
Recent progress made in molecular biology, biotechnology, and genetics, especially in identifying, cloning, sequencing and characterization of normal and pathogenic genes, has led to the development of genetic therapy. Major efforts in the field can be summarized in two general approaches: gene therapy and antisense therapy. The second is to deliver to the target cells antisense molecules that target to mRNA with which they can hybridize and specifically inhibit the expression of pathogenic genes. Antisense oligonucleotides offer the possibility of specific, rational, genetic-based therapeutics. With encouraging results from preclinical and clinical studies of antisense oligonucleotides in the past decade, significant progress has been made in developing antisense therapy, with the first antisense drug now being approved for clinical use. In this article, we will discuss approaches to developing these drugs from preclinical to clinical settings. Of particular interest for the area of human cancer therapy, several cancer targets, including bcl-2, BCR-ABL, C-raf-1, Ha-ras, c-myc, PKC, PKA, p53 and MDM2, are reviewed as examples to illustrate the progress in this field and emphasize the importance of target selection and advanced antisense chemistry in the development of antisense therapy.
Current Cancer Drug Targets
Title: Antisense Anticancer Oligonucleotide Therapeutics
Volume: 1 Issue: 3
Author(s): Hui Wang, Gautam Prasad, John K. Buolamwini and Ruiwen Zhang
Affiliation:
Abstract: Recent progress made in molecular biology, biotechnology, and genetics, especially in identifying, cloning, sequencing and characterization of normal and pathogenic genes, has led to the development of genetic therapy. Major efforts in the field can be summarized in two general approaches: gene therapy and antisense therapy. The second is to deliver to the target cells antisense molecules that target to mRNA with which they can hybridize and specifically inhibit the expression of pathogenic genes. Antisense oligonucleotides offer the possibility of specific, rational, genetic-based therapeutics. With encouraging results from preclinical and clinical studies of antisense oligonucleotides in the past decade, significant progress has been made in developing antisense therapy, with the first antisense drug now being approved for clinical use. In this article, we will discuss approaches to developing these drugs from preclinical to clinical settings. Of particular interest for the area of human cancer therapy, several cancer targets, including bcl-2, BCR-ABL, C-raf-1, Ha-ras, c-myc, PKC, PKA, p53 and MDM2, are reviewed as examples to illustrate the progress in this field and emphasize the importance of target selection and advanced antisense chemistry in the development of antisense therapy.
Export Options
About this article
Cite this article as:
Hui Wang , Gautam Prasad , John K. Buolamwini and Ruiwen Zhang , Antisense Anticancer Oligonucleotide Therapeutics, Current Cancer Drug Targets 2001; 1 (3) . https://dx.doi.org/10.2174/1568009013334133
DOI https://dx.doi.org/10.2174/1568009013334133 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
LC/MS/MS Profiling of Tissue Oxysterols and its Application in Dextran Sodium Sulphate Induced Mouse Colitis Models
Current Topics in Medicinal Chemistry Recent Advances in Self-Assembled Fluorescent DNA Structures and Probes
Current Topics in Medicinal Chemistry The Microbiota and Gut-Brain Axis: Contributions to the Immunopathogenesis of Schizophrenia
Current Pharmaceutical Design Editorial [Hot Topic: Novel Non-Cytotoxic Approaches For Cancer Therapy: Potential Targets and Pathways Amenable to Single Agent Multimodal Therapeutic Approaches (Guest Editor: Andrew Mazar)]
Current Cancer Drug Targets Ultrasound-Assisted 3-Component Reaction in Acetic Acid Alone: Catalyst / Promoter / Ligand Free Synthesis of Bioactive Pyrazolo[1,5-a]pyrimidines
Letters in Drug Design & Discovery Multidrug Resistance in Cancer Chemotherapy and Xenobiotic Protection Mediated by the Half ATP-Binding Cassette Transporter ABCG2
Current Medicinal Chemistry - Anti-Cancer Agents Dietary Phytochemicals in the Chemoprevention and Treatment of Hepatocellular Carcinoma: In Vivo Evidence, Molecular Targets, and Clinical Relevance
Current Cancer Drug Targets Cardiovascular Remodeling Induced by Passive Smoking
Inflammation & Allergy - Drug Targets (Discontinued) Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Advances in Colloidal Processing of Rare Earth Particles
Current Smart Materials (Discontinued) Computer-aided Diagnosis of Skin Cancer: A Review
Current Medical Imaging Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities
Current Molecular Medicine The Medicinal Potential of Natural Products for the Development of Anti- Influenza Agents
Current Drug Targets Nonviral Gene Therapy
Current Gene Therapy Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets QSAR study on N- (Aryl)-4-(Azolylethyl) Thiazole-5-Carboxamides: Novel Potent Inhibitors of VEGF Receptors I and II
Medicinal Chemistry Current Biomarkers for Lung Cancer
Current Signal Transduction Therapy Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Human Serum Albumin Conjugated Biomolecules for Cancer Molecular Imaging
Current Pharmaceutical Design An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design